Drug Profile
Danoprevir/ritonavir - Roche
Alternative Names: Ritonavir-boosted danoprevirLatest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Roche
- Developer Ascletis; Roche
- Class Antivirals; Carboxylic acids; Cyclopropanes; Isoindoles; Macrocyclic compounds; Pyrrolidines; Small molecules; Sulfonamides; Thiazoles
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hepatitis C
- Clinical Phase Unknown COVID-19 pneumonia
Most Recent Events
- 30 Dec 2022 Clinical development is ongoing in COVID-19 pneumonia in China (PO) (ChiCTR2000030259)
- 29 Jan 2019 Chemical structure information added
- 28 Nov 2018 No recent reports of development identified for phase-I development in Hepatitis-C(Monotherapy, In volunteers) in China (PO, Tablet)